APA (7th ed.) Citation

C, W., LL, B., J, F., A, B., A, H., S, I., . . . A, Z. (2024). Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: A population-based observational study. The Lancet regional health. Europe, 47, 101092. https://doi.org/10.1016/j.lanepe.2024.101092

Chicago Style (17th ed.) Citation

C, Weiß, et al. "Efficacy and Safety of Gene Therapy with Onasemnogene Abeparvovec in Children with Spinal Muscular Atrophy in the D-A-CH-region: A Population-based Observational Study." The Lancet Regional Health. Europe 47 (2024): 101092. https://doi.org/10.1016/j.lanepe.2024.101092.

MLA (9th ed.) Citation

C, Weiß, et al. "Efficacy and Safety of Gene Therapy with Onasemnogene Abeparvovec in Children with Spinal Muscular Atrophy in the D-A-CH-region: A Population-based Observational Study." The Lancet Regional Health. Europe, vol. 47, 2024, p. 101092, https://doi.org/10.1016/j.lanepe.2024.101092.